Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
### Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Maintenance of healing of erosive esophagitis
* Treatment of duodenal ulcers
* Treatment of gastric ulcers
### Adult Dosing
* **Erosive esophagitis:** 40 mg once daily for up to 8 weeks. A further 8 weeks may be considered for patients not healed after the initial course.
* **Maintenance of healing of erosive esophagitis:** 40 mg once daily.
* **GERD (symptomatic relief):** 40 mg once daily for up to 4 weeks.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg twice daily, but may be increased. Doses have ranged from 80 mg to 240 mg daily.
* **Duodenal ulcers:** 40 mg once daily for up to 4 weeks.
* **Gastric ulcers:** 40 mg once daily for up to 4 weeks.
### Pediatric Dosing
* **Erosive esophagitis (ages 5-16 years):** 40 mg once daily for up to 4 weeks.
* **GERD (ages 5-16 years):** 20 mg once daily for up to 4 weeks.
* Dosing in pediatric patients under 5 years is not established.
### Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose should not exceed 40 mg.
* **Renal Impairment:** No dose adjustment is generally needed.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
* **Common:** Diarrhea, headache, abdominal pain, nausea, dizziness, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia, fundic gland polyps, potential for vitamin B12 deficiency with prolonged use.
### Key Drug Interactions
* **Warfarin:** Monitor INR closely as pantoprazole may increase INR and prothrombin time.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, erlotinib, nelfinavir.
* **CYP2C19 substrates:** Clopidogrel (potential for reduced antiplatelet effect, though clinical significance is debated).
### Monitoring
* Electrolytes (especially magnesium, calcium, potassium) with long-term therapy.
* Bone mineral density in patients at risk for osteoporosis.
* Symptoms of *C. difficile* infection.
### Clinical Pearls
* Administer pantoprazole tablets 30 minutes before a meal.
* Do not crush or chew enteric-coated granules or tablets. If a patient cannot swallow whole tablets, the 40 mg delayed-release oral suspension can be used.
* Long-term use of PPIs is associated with increased risks of fractures, *C. difficile* infection, and hypomagnesemia. Consider the lowest effective dose and shortest duration of therapy.
* Discontinuation should be gradual to avoid rebound acid hypersecretion.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace comprehensive drug information resources. Always consult the most current prescribing information approved by regulatory agencies and consider individual patient factors.
